Quarterly report pursuant to Section 13 or 15(d)

Revenue Disaggregation

v3.23.2
Revenue Disaggregation
 3 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Disaggregation

 

Note 10. Revenue Disaggregation

 

The Company generates product revenues from products which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services which are provided to medical device manufacturers.

 

The following table presents the Company’s disaggregated revenues by source: 

               
    Three Months Ended June 30,  
Product   2023     2022  
Human Care   $ 2,750,000     $ 2,168,000  
Animal Care     578,000       787,000  
Total Product     3,328,000       2,955,000  
Service and Royalty     99,000       1,028,000  
Total   $ 3,427,000     $ 3,983,000  

 

The following table shows the Company’s revenues by geographic region: 

               
    Three Months Ended June 30,  
    2023     2022  
United States   $ 806,000     $ 871,000  
Europe     1,070,000       841,000  
Asia     862,000       920,000  
Latin America     487,000       1,048,000  
Rest of the World     202,000       303,000  
Total   $ 3,427,000     $ 3,983,000  

 

The Company’s service revenues in Latin America amounted to $99,000 and $1,028,000 for the three months ended June 30, 2023 and 2022, respectively.